Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + CapeOx in RAS/BRAF wild-type metastatic colorectal cancer
NCT04854668Phase 3Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anlotinib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Progression-Free Survival at 15 months. Started May 2021; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04854668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854668.